Embecta Corp. (“Embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, announces that it has entered into a definitive agreement to acquire Owen Mumford Holdings Limited (“Owen Mumford”), a privately held, UK‑based innovator and manufacturer of medical devices and drug‑delivery technologies, in a transaction valued at up to £150 million. Under the terms of the agreement, embecta will acquire Owen Mumford for an upfront cash payment of £100 million at closing (subject to customary adjustments, including for closing net cash), and up to an additional £50 million in performance-based payments based on net sales of the Aidaptus® next generation auto-injector platform in the three-year period following the closing.
Read the full article: embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited //
Source: https://investors.embecta.com/news-releases/news-release-details/embecta-announces-definitive-agreement-acquire-owen-mumford